Strong Market Presence CuraScript, Inc. operates within the highly competitive pharmaceutical manufacturing industry in the US, with a substantial employee base of up to 5,000, indicating a significant market footprint and potential for large-scale distribution opportunities.
Revenue Potential With reported revenues ranging from 250 million to 500 million dollars, CuraScript exhibits solid financial performance, opening avenues for upselling advanced pharmaceutical solutions and expanding specialty pharmacy services.
Specialty Pharmacy Focus As part of Accredo Health Group, the specialty pharmacy segment is a key growth area, suggesting opportunities to introduce innovative pharmaceutical products tailored for complex and chronic condition treatments.
Technology and Digital Engagement Given the emphasis on their website and LinkedIn presence, there is potential for digital marketing collaborations and technology-driven supply chain enhancements to improve service efficiency and patient engagement.
Competitive Positioning Compared to peers like CVS Specialty and Diplomat Pharmacy, CuraScript's scale and backing by Express Scripts position it well for partnerships and expanding access to niche markets in specialty pharmaceuticals.
| CuraScript, Inc. An Express Scripts Co. Email Formats | Percentage |
| First.Last@curascript.com | 84% |
| FLast@curascript.com | 14% |
| Last.First@curascript.com | 1% |
| LastF@curascript.com | 1% |
Pharmaceutical ManufacturingUnited States1001-5000 Employees
The specialty pharmacy business of CuraScript, Inc., an Express Scripts company, is now owned and operated by Accredo Health Group, Inc., an Express Scripts company. To see what's new, visit the Accredo LinkedIn page or accredo.com.
Company Overview
Funding & FinancialsCuraScript, Inc. An Express Scripts Co.'s revenue is estimated to be in the range of $250M$500M
Funding & FinancialsCuraScript, Inc. An Express Scripts Co.'s revenue is estimated to be in the range of $250M$500M
1-888-653-2347 
support@leadiq.com